Jump to Navigation

Facebook Connect

User login

Communications CSS

News Stories

Aug, 2017

The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events.  Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels.  These favorable lipid changes were associated with a significant reduction in cardiovascular events

0
No votes yet
Name: NLA News
Aug, 2017

The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at lipidboard.org/moc.

4.5
Average: 4.5 (2 votes)
Name: NLA News
Jul, 2017

JACKSONVILLE, Fla. – The Foundation of the NLA launched its RADAR (RAre Disease AwarReness) campaign and redesigned website, learnyourlipids.com on Monday.

0
No votes yet
Name: NLA News

Pages



by Dr. Radut.